Perspectives on the efficacy and indications for preimplantation genetic screening: where are we now?

Abstract

Given that the majority of failed implantations and early pregnancies reasonably may be attributed to embryo aneuploidy, the logical foundation for the use of preimplantation genetic screening (PGS) in cycles of in vitro fertilization (IVF) seems undeniably sound. If abnormal embryos having no implantation or advanced developmental potential can be identified accurately and excluded, and if only normal, euploid embryos are transferred, improved outcomes certainly should be expected, at least in women at a high risk of aneuploidy, if not in all women. Those at greatest risk of aneuploidy and therefore presumed most likely to benefit from PGS include women of advanced maternal age, women having recurrent unexplained miscarriages or implantation failure after transfer of good-quality embryos, and women with partners having severe male factor infertility.